Ke Bin, Jin Peng, Wang Xue-Jun, Zhang Ru-Peng, Liu Ning, Ma Gang
Department of Gastric Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Tianjin, 300060, China.
Sci Rep. 2025 Aug 7;15(1):28934. doi: 10.1038/s41598-025-14342-z.
Integrin subunit alpha V (ITGAV), a subunit of the integrin receptor, is involved in many types of cancers. In order to explore the potential mechanisms of ITGAV in cancers, we carried out a comprehensive pan-cancer analysis using public database. In this study, ITGAV expression in different cancers and the relationship between ITGAV and clinic-pathological features, prognosis, genetic alteration, epigenetic modification, and tumor immune microenvironment were systemically analyzed. Gene enrichment analysis was performed to explore potential functions of ITGAV in gastric cancer (GC). GC tissue microarrays and in vitro cell experiments were used to verify the prediction results in GC. The results revealed that ITGAV was variably expression in different cancers, and ITGAV had a certain prognostic and diagnostic value in most cancers, including GC. ITGAV expression was found to be related to genetic alteration, DNA methylation, immune checkpoint gene, and immune cell infiltration in multiple cancers. Functional analyses revealed that ITGAV was involved in the regulation of EMC remodeling, ferroptosis, and cuproptosis in GC. In vitro experiments verified that ITGAV was correlated with GC cell proliferation, apoptosis, migration, and invasion. Our study demonstrated that ITGAV can be used as an effective prognostic and immunological biomarker for multiple cancers. ITGAV can promote GC malignant progression and could serve as a potential therapeutic target for GC treatment.
整合素αV亚基（ITGAV）是整合素受体的一个亚基，与多种癌症相关。为了探究ITGAV在癌症中的潜在机制，我们利用公共数据库进行了全面的泛癌分析。在本研究中，系统分析了ITGAV在不同癌症中的表达以及ITGAV与临床病理特征、预后、基因改变、表观遗传修饰和肿瘤免疫微环境之间的关系。进行基因富集分析以探究ITGAV在胃癌（GC）中的潜在功能。使用GC组织芯片和体外细胞实验验证GC中的预测结果。结果显示，ITGAV在不同癌症中表达各异，且在包括GC在内的大多数癌症中具有一定的预后和诊断价值。发现ITGAV表达与多种癌症中的基因改变、DNA甲基化、免疫检查点基因和免疫细胞浸润有关。功能分析表明，ITGAV参与GC中内质网重塑、铁死亡和铜死亡的调节。体外实验证实ITGAV与GC细胞增殖、凋亡、迁移和侵袭相关。我们的研究表明，ITGAV可作为多种癌症有效的预后和免疫生物标志物。ITGAV可促进GC的恶性进展，并可作为GC治疗的潜在靶点。
